In recent years, the conversation around substance employ disorders has evolved significantly, with medical professionals and policymakers exploring innovative approaches to address the devastating impact of crack cocaine addiction. One controversial proposal gaining attention in parts of Europe involves the medical prescription of cocaine hydrochloride – a pharmaceutical-grade form of the drug – as a potential harm reduction strategy for individuals with severe, treatment-resistant crack dependence. This approach, sometimes referred to as “heroin-assisted treatment” adapted for stimulants, aims to stabilize chaotic drug use by providing regulated doses under clinical supervision, thereby reducing the harms associated with illicit market products and compulsive purchasing behaviors.
The idea stems from long-standing models of opioid substitution therapy, such as methadone or buprenorphine maintenance, which have demonstrated efficacy in reducing illicit opioid use, overdose deaths, and crime when implemented within comprehensive treatment frameworks. Proponents argue that for a subset of crack users who have not responded to conventional interventions like cognitive behavioral therapy or contingency management, access to pharmaceutical cocaine could disrupt the cycle of bingeing, crashing, and re-dosing that characterizes severe stimulant use disorder. By eliminating the need to seek unpredictable and often adulterated street drugs, such programs might improve engagement with healthcare services and create opportunities for broader psychosocial support.
However, the concept remains highly contentious, particularly due to cocaine’s classification as a Schedule II substance under the United Nations Convention on Psychotropic Substances and its high potential for misuse. Critics warn that prescribing cocaine could inadvertently normalize its use, divert resources from evidence-based prevention and treatment, or pose risks of diversion to the illicit market. Regulatory bodies in most countries, including the United States and Switzerland, have not approved cocaine for maintenance treatment, citing insufficient long-term data on safety and efficacy compared to established alternatives.
Despite these concerns, limited pilot programs have emerged in specific jurisdictions. In Spain, for example, researchers at the Hospital de la Santa Creu i Sant Pau in Barcelona conducted a small-scale study examining injectable cocaine hydrochloride as part of a supervised injection facility protocol for individuals with severe crack use disorder. Preliminary findings, published in the peer-reviewed journal Drug and Alcohol Dependence, indicated reductions in self-reported crack consumption and improvements in social stability among participants, though the study lacked a control group and involved fewer than 30 individuals[1]. Similarly, a feasibility assessment in the Netherlands explored oral cocaine formulations within a clinical setting, emphasizing strict eligibility criteria and intensive monitoring[2].
These initiatives remain exceptional and heavily regulated, operating under special exemptions or research protocols rather than standard medical practice. Access is typically restricted to adults with a documented history of long-term, daily crack use who have failed multiple prior treatment attempts, and participation requires informed consent, regular medical evaluations, and integration with counseling or social work services. Importantly, such programs do not constitute a “cure” for addiction but rather aim to reduce immediate harms whereas creating pathways toward sustained recovery.
The broader context of rising crack-related harms in certain regions underscores the urgency of exploring all viable interventions. In parts of Latin America and the Caribbean, increased availability of coca paste and crack derivatives has correlated with spikes in emergency department visits and infectious disease transmission among people who smoke or inject the substance. Meanwhile, in select European cities, harm reduction organizations have reported shifts in crack use patterns, including increased frequency of use and higher purity levels in some illicit supplies, prompting renewed interest in low-threshold, low-barrier models of care.
Medical experts stress that any consideration of pharmaceutical cocaine must be grounded in rigorous ethical frameworks and public health principles. The World Health Organization has not endorsed cocaine-assisted therapy, instead recommending that member states prioritize scaling up access to evidence-based psychosocial interventions, contingency management, and emerging pharmacological options like modafinil or topiramate, which have shown promise in clinical trials for reducing crack cravings[3]. Nevertheless, ongoing research into the neurobiology of stimulant dependence continues to inform debates about whether maintenance approaches could play a role in a diversified treatment landscape.
As discussions continue, stakeholders emphasize the importance of centering the voices of people with lived experience. Advocacy groups such as the European Network of People who Use Drugs (EuroNPUD) have called for greater inclusion of affected communities in designing harm reduction services, arguing that top-down policies often fail to address the complex social determinants – including poverty, homelessness, and trauma – that underlie persistent substance use challenges[4]. Any future expansion of cocaine-assisted models would require transparent evaluation, community oversight, and safeguards against misuse.
For now, the prescription of cocaine remains a subject of specialized inquiry rather than widespread clinical application. Health authorities in most jurisdictions continue to advise individuals struggling with crack use to seek support through established channels, including addiction specialists, community health centers, and peer-led recovery groups. In the United States, the Substance Abuse and Mental Health Services Administration (SAMHSA) maintains a national helpline (1-800-662-HELP) offering confidential, free assistance 24/7 for those seeking treatment information or local referrals[5]. Similarly, in the UK, the NHS provides guidance on accessing drug treatment services through local councils or general practitioners[6].
The next official update on this topic is expected from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), which is scheduled to release its annual report on drug trends and responses in June 2025. This publication will include updated data on harm reduction innovations across member states and may feature analysis of emerging stimulant treatment approaches.
As the global community seeks effective, compassionate responses to substance use disorders, the dialogue around medical cocaine underscores the need for evidence-driven, ethically sound innovation. Readers are encouraged to share their perspectives and experiences in the comments below and to spread awareness by sharing this article with others interested in public health and harm reduction.